Elżbieta G.
- Country
- Poland
- Department
- N/A
Research Overview
- A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
- Long-Term Safety, Tolerability, and Efficacy of Zasocitinib in Adults With Active Psoriatic Arthritis: A Phase 3 Extension Study
- Efficacy and Safety Evaluation of Deucravacitinib in Biologic-Naïve Patients with Active Psoriatic Arthritis: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 178 of 393 partner sites.
Specializations
Rheumatology Focus
The investigator specializes in treating psoriatic arthritis, with particular emphasis on therapeutic approaches for patients who have not previously received biological disease-modifying treatments.
- Biologic-naive patient care
- Advanced therapeutic interventions
- Autoimmune joint conditions
Their expertise extends to evaluating novel treatment modalities for active psoriatic arthritis manifestations.
Immunology Applications
The investigator focuses on innovative immunomodulatory therapies, including research into targeted treatments such as sonelokimab, deucravacitinib, and zasocitinib for autoimmune conditions.
- Novel therapeutic agents
- Immune system modulation
- Treatment response assessment
Their work encompasses the evaluation of subcutaneous and oral therapeutic options for inflammatory joint conditions.
Clinical Assessment
The investigator has developed expertise in therapeutic efficacy evaluation with specific focus on standardized response criteria in rheumatic conditions.
- Response criteria measurement
- Safety profile assessment
- Treatment optimization
Their clinical assessment work includes comprehensive evaluation of therapeutic responses in inflammatory arthritis.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.